Lawsuit Filed by GEICO Against Hudson Regional Hospital Is Dismissed

December 23, 2020

Lawsuit filed by GEICO against Hudson Regional Hospital has been dismissed. (Eastern District Federal Court Docket # 20cv01098). The lawsuit was related to billing practices at healthcare entities associated with Hudson Regional Hospital and its owner Yan Moshe.

Claims were dismissed against all the parties named in the suit, including:

  • Hudson Regional Hospital
  • Yan Moshe
  • Dr. Regina Moshe
  • Dr. Nizar Kifaieh
  • CitiMed

“We are pleased with this voluntary dismissal by GEICO,” says Yan Moshe, Chairman of Hudson Regional.  “This represents the beginning to a transparent and highly functional relationship that focuses on access to high-quality medical care to the millions of GEICO- insured patients in New York and New Jersey.”

“I couldn’t have asked for a better outcome for this claim with GEICO,” says Dr. Regina Moshe, CEO of CitiMed.  “At CitiMed, we are proud to provide excellent care to all patients and we are especially happy to continue a great relationship with GEICO-insured customers.”

“On behalf of our staff, I am very proud of the reputation we have established at Hudson Regional Hospital as its high-quality acute care facility during our three years of operation,” said Dr. Nizar Kifaieh, President and CEO of Hudson Regional Hospital.  “The voluntary dismissal of the claim by GEICO against HRH and Premier Anesthesia was a logical resolution and a testament to our standing in the community.”

“Importantly, after a productive dialogue with GEICO, including an appeal to the Federal 2nd Circuit Court, the lawsuit has been dismissed,” said Keith J. Roberts, counsel to Mr. Moshe and the Hospital. “Our clients were pleased with the outcome,” he added.

“The outcome is a final disposition, forever precluding the re-litigation of any of the claims which were the subject of their previously filed Complaint,” said Charles Horn, Esq. counsel to Regina Moshe, MD, and CitiMed.

“The dismissal of this lawsuit lays to rest any disagreements between GEICO and Hudson Regional, and provides a lasting framework for open communication, transparency and mutual cooperation,” said Russell Friedman, long-time counsel to Mr. Moshe and Hudson Regional Hospital.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version